US2023338617A1PendingUtilityA1

Methods and compositions for repair of cartilage using an in vivo bioreactor

Assignee: SPINALCYTE LLCPriority: Feb 7, 2006Filed: Jun 13, 2023Published: Oct 26, 2023
Est. expiryFeb 7, 2026(expired)· nominal 20-yr term from priority
A61L 27/3817A61K 45/06A61K 35/32A61K 35/33A61F 2/30756A61F 2/441A61K 38/18A61L 27/3852A61L 27/3895C12N 5/0655A61F 2/3099A61F 2/32A61F 2/38A61F 2/3804A61F 2/40A61F 2002/2817A61F 2002/286A61F 2002/30062A61F 2002/30586A61F 2002/30677A61F 2002/30762A61F 2002/30764A61F 2002/30766A61F 2002/444A61F 2002/4445A61F 2002/445A61F 2002/4635A61F 2210/0004C12N 2500/02C12N 2500/38C12N 2501/155C12N 2506/1307C12N 2521/00C12N 2533/74A61P 19/00A61P 19/04A61P 31/04A61P 31/10A61P 31/12A61P 41/00A61P 43/00A61L 2430/06
88
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A composition comprising chondrocyte-like cells derived from fibroblasts. 
     
     
         2 . The composition of  claim 1 , wherein said chondrocyte-like cells produce one or more of aggrecan, type II collagen, Sox-9 protein, cartilage link protein, perlecan, and sulfated proteoglycan. 
     
     
         3 . The composition of  claim 1 , wherein the fibroblasts are dermal fibroblasts, tendon fibroblasts, synovial fibroblasts, or ligament fibroblasts. 
     
     
         4 . The composition of  claim 1 , wherein the fibroblasts are autologous or allogeneic. 
     
     
         5 . The composition of  claim 1 , wherein the fibroblasts are autologous human dermal fibroblasts (HDFs) or neonatal HDFs. 
     
     
         6 . A kit comprising the composition of  claim 1 . 
     
     
         7 . The kit of  claim 6 , wherein the chondrocyte-like cells are housed in a syringe.

Join the waitlist — get patent alerts

Track US2023338617A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.